title: [Possible framework and best practices in the future for prescriptions outside market authorization indications for rare diseases?].
authors.affiliation: jwesterloppe@celgene.com
authors.forename: Jeremie
authors.initials: J
authors.lastname: Westerloppe
mesh_terms: D017277:Drug Approval / Q000331:legislation & jurisprudence; D011307:Drug Prescriptions; D058492:Drug Repositioning; D006801:Humans; D009313:National Health Programs / Q000331:legislation & jurisprudence; D017410:Practice Guidelines as Topic; D035583:Rare Diseases / Q000188:drug therapy*; D012309:Risk-Taking; D012955:Societies, Medical / Q000331:legislation & jurisprudence / Q000458:organization & administration